Author + information
- Robin Kraak1,
- Joelle Elias2,
- Deborah Kalkman3,
- Karel Koch4,
- Jose PS. Henriques4,
- Jan Piek5,
- Jan Baan6,
- Marije Vis7,
- Jan Tijssen8,
- Robert de Winter9 and
- Joanna Wykrzykowska10
- 1AMC Heartcentre, Academic Medical Centre - Un, Amsterdam, Netherlands
- 2Academic Medical Centre (AMC) - University of Amsterdam, Amsterdam, Netherlands
- 3Academic Medical Center, Amsterdam, Netherlands
- 4Academic Medical Center - University of Amsterdam, Amsterdam, Netherlands
- 5University of Amsterdam, Amsterdam, Netherlands
- 6AMC, Amsterdam, Netherlands
- 7AMC Amsterdam, Amsterdam, Netherlands
- 8AMC-UVA, Naarden, Netherlands
- 9Academisch Medisch Centrum, Amsterdam, Netherlands
- 10Academic Medical Center Amsterdam, Amsterdam, Netherland
Diabetic patients are known to have an increased risk of adverse clinical events after percutaneous coronary intervention with DES. However, there was no difference in clinical outcomes between diabetic and non-diabetic patients treated with ABSORB BVS at one year in a pooled analysis of the ABSORB and the SPIRIT trials. Two-year clinical outcomes of diabetic patients after BVS implantation have not been reported. Therefore we evaluated the clinical outcomes two-year after BVS implantation in diabetic patients of the Amsterdam Absorb Registry at two-year follow-up.
Patients treated with BVS in routine clinical practice were included in this registry. Clinical outcomes assessed were Death, Myocardial Infarction (MI), Stent Thrombosis (ST), Target Vessel Revascularization (TVR), Target Lesion Revascularization (TLR) and Target Vessel Failure (TVF).
The registry included 135 patients, of which 27 (20%) were diabetics. Diabetic patients had a significantly higher revascularization rate compared to patients without diabetes (TLR: 23.8% vs 8.5%; p=0.029 and TVR: 27.7% vs 10.3% p=0.024). Diabetic patients demonstrated also a higher incidence of the composite endpoint of TVF (27.7% vs 11.3%; p=0.037). There was no difference in the incidence of mortality, myocardial infarction or scaffold thrombosis.
In a patient registry reflecting daily clinical practice, including both high-risk lesions and patients, the use of the ABSORB BVS in diabetic patients is associated with increased revascularization rates compared to non-diabetics at two-year follow-up.
CORONARY: Stents: Bioresorbable Vascular Scaffolds